This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
6 Factors to Bet on Wall Street: ETFs to Buy
by Sanghamitra Saha
The Nasdaq Composite and the S&P 500 hit new all-time high Friday. However, there are chances of further rally.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
2 ETFs to Watch for Outsized Volume on Healthcare & Materials
by Sanghamitra Saha
In the last trading session, PTH and GUNR traded with an outsized volume.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
5 Top-Ranked ETFs With Lower P/E Ratio
by Sweta Killa
We have highlighted five ETFs from different zones of the market that are currently undervalued and could generate solid returns in a rising stock market.
4 Top-Ranked Sector ETFs to Buy Now
by Sweta Killa
After a solid start to the third quarter, the Wall Street rally fizzled out in mid-August. The weak trend is likely to continue given rising rates, recession fears, and historical underperformance in September.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
5 Undervalued ETFs to Buy for Second Half 2022
by Sweta Killa
Persistent high inflation and an economic downturn caused by a hawkish Fed continued to weigh on investor sentiment. This has made the stocks cheaper, compelling investors to buy the dip.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
An ETF Retirement Portfolio for 2021
by Sanghamitra Saha
Here are a few ETF strategies that could be considered in a retirement portfolio.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Trump vs. Biden First Presidential Debate: ETFs in Focus
by Sweta Killa
After months of campaign, President Donald Trump and Democratic nominee Joe Biden will come face-to-face on debate stage on Sep 30 in Cleveland.
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Biotech ETFs Soars on Gilead-Immunomedics Deal
by Sweta Killa
The acquisition will expand Gilead's portfolio of treatments for various types of cancer.
5 ETFs Jump After Three-Day Rout: Will The Rally Last?
by Sweta Killa
We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.
Will Novavax ETFs Gain on Coronavirus Vaccine Progress?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in the coronavirus vaccine development amid the coronavirus outbreak.
ETF Winners & Losers From Wall Street's Worst Day Since June
by Sweta Killa
After a massive rally, Wall Street suffered its worst day in almost three months as investors' dumped the high-flying technology stocks.
ETFs Set to Surge on Virtual Healthcare Deal
by Sweta Killa
The ongoing boom in online care and consultations has led to merger & acquisition activity in the telehealth services space.
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.